{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-23-000072","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.647633+00:00","generated_at":"2026-06-15T16:16:04.027002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M","bullets":["Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).","Net loss $13.9M ($0.32/share) vs $14.9M ($0.35) in Q1 2022.","Placed three Growth Direct systems; two systems validated in the quarter.","Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 placements.","Appointed Michael Wysocki SVP Sales and Marketing; cash $122.1M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-23-000072","json":"https://secwatch.observer/filing/0001380106-23-000072.json","markdown":"https://secwatch.observer/filing/0001380106-23-000072.md","text":"https://secwatch.observer/filing/0001380106-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/0001380106-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/rpid-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:16:04.027002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ab9404e4081a91f5854d596769caeadb3989e04","claim":"RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2023 results: revenue $5.0 million, net income $13.9 million, EPS $0.32. Guidance reaffirmed.","evidence_excerpt":"expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000072/0001380106-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.0 million"},{"label":"Net income","value":"$13.9 million"},{"label":"EPS","value":"$0.32"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}